Cencora, Inc.COR
時価総額
$709億
PER
医薬品調達・卸売と物流、メーカー向け商業化支援の世界最大手。血漿製品やワクチン、バイオ・細胞・遺伝子治療向け専門流通とデータ支援サービスを展開。2024年11月に眼科団体を約46億ドルで買収合意、2023年1月に専門サービス企業を約14.73億ドルで買収。米国・欧州中心に展開。
| 2010年 9月30日 | 2011年 9月30日 | 2012年 9月30日 | 2013年 9月30日 | 2014年 9月30日 | 2015年 9月30日 | 2016年 9月30日 | 2017年 9月30日 | 2018年 9月30日 | 2019年 9月30日 | 2020年 9月30日 | 2021年 9月30日 | 2022年 9月30日 | 2023年 9月30日 | 2024年 9月30日 | |
| Net income | - | - | - | - | - | - | - | - | 1,616 | 854 | -3,400 | 1,545 | 1,667 | 1,733 | 1,519 |
| Depreciation | 83 | 105 | 119 | 139 | 162 | 188 | 233 | 262 | 318 | 321 | 291 | 327 | 391 | 419 | 448 |
| Amortization | 21 | 21 | 29 | 32 | 31 | 62 | 160 | 170 | 192 | 176 | 117 | 188 | 319 | 562 | 671 |
| Provision for credit losses | 43 | 39 | 26 | 20 | 27 | 8 | 13 | 9 | 17 | 25 | 12 | 12 | 26 | 54 | 41 |
| Deferred Income Tax Expense (Benefit) | 85 | 195 | 61 | 26 | 39 | 23 | -131 | 319 | -796 | 29 | -1,545 | 335 | 196 | -119 | -102 |
| Share-based compensation expense | 31 | 28 | 26 | 36 | 43 | 61 | 65 | 62 | 62 | 59 | 74 | 100 | 93 | 125 | 148 |
| LIFO (credit) expense | - | - | - | - | - | - | 200 | -158 | 67 | -22 | 7 | -203 | 67 | 205 | -52 |
| Asset Impairment Charges | - | - | - | - | - | - | - | - | 30 | 570 | - | 32 | 81 | - | 418 |
| Gain on divestiture of businesses | - | - | - | - | - | 13 | - | 4 | - | - | - | - | 56 | 41 | - |
| Inflationary Accounting Impact | - | - | - | - | - | - | - | - | - | - | - | - | 52 | 96 | 55 |
| Loss (gain) on remeasurement of equity investments | - | - | - | - | - | - | - | - | - | - | - | 65 | 5 | 0 | -16 |
| Other, net | - | 4 | 1 | -2 | 7 | 12 | 5 | -11 | 13 | 23 | 3 | -29 | -12 | -4 | -24 |
| Accounts receivable | -61 | 35 | -42 | 2,313 | 938 | 1,479 | 913 | 1,278 | 658 | 1,242 | 1,629 | 930 | 1,660 | 2,712 | 2,784 |
| Inventories | 243 | 272 | 200 | 1,487 | 957 | 836 | 1,107 | 431 | 5 | 168 | 1,621 | 1,116 | 665 | 2,183 | 1,480 |
| Income tax receivable | - | - | - | - | - | - | - | - | - | - | 483 | -267 | -49 | -102 | 11 |
| Prepaid expenses and other assets | -10 | 27 | -46 | 170 | -21 | 37 | 46 | -34 | 57 | 7 | -28 | -141 | -103 | -109 | -168 |
| Accounts payable | - | - | - | - | - | - | 3,012 | 1,473 | 859 | 1,561 | 3,301 | 2,049 | 3,321 | 6,103 | 4,968 |
| Accrued expenses | 385 | 406 | 421 | 3,818 | 2,318 | 5,126 | 83 | 661 | -538 | - | 524 | 372 | -457 | 51 | 149 |
| Income taxes payable and other liabilities | - | - | - | - | - | - | - | - | - | - | - | - | -330 | -196 | -205 |
| Long-term accrued litigation liability | - | - | - | - | - | - | - | - | - | - | 6,199 | -237 | -500 | -400 | -506 |
| NET CASH PROVIDED BY OPERATING ACTIVITIES | 1,109 | 1,168 | 1,305 | 788 | 1,463 | 3,920 | 3,178 | 1,504 | 1,411 | 2,344 | 2,207 | 2,667 | 2,703 | 3,911 | 3,485 |
| Capital expenditures | 185 | 168 | 164 | 202 | 264 | 232 | 465 | 466 | 336 | 310 | 370 | 438 | 496 | 458 | 487 |
| Cost of acquired companies, net of cash acquired | - | 45 | 776 | - | 9 | 2,633 | 2,731 | 62 | 785 | 64 | - | 5,563 | 134 | 1,410 | 70 |
| Cost of equity investments | - | - | - | - | - | - | 19 | 11 | - | - | 56 | 163 | 18 | 743 | 30 |
| Non-customer note receivable | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50 |
| Proceeds from divestiture of businesses | - | - | - | 330 | - | 17 | - | 12 | - | - | - | - | 273 | - | - |
| Other, net | - | - | - | - | -7 | -3 | 14 | -3 | -11 | 2 | -10 | -8 | -1 | -9 | -19 |
| NET CASH USED IN INVESTING ACTIVITIES | -184 | -212 | -948 | 117 | -384 | -2,931 | -3,169 | -498 | -1,111 | -376 | -380 | -6,142 | -368 | -2,602 | -618 |
| Proceeds from Issuance of Debt | - | - | - | - | - | 1,996 | 1,000 | - | 1,314 | 507 | 599 | 3,167 | 155 | 158 | 688 |
| Senior notes and other loan repayments | - | - | - | - | - | - | - | - | - | - | - | - | 1,239 | 811 | 663 |
| Proceeds from Lines of Credit | - | - | - | - | - | - | - | - | - | - | - | - | 4,833 | 78,218 | 69,703 |
| Repayments under revolving and securitization credit facilities | - | - | - | - | - | - | - | - | - | - | 150 | 5,084 | 4,672 | 78,188 | 70,114 |
| Purchases of common stock | 470 | 841 | 1,162 | 484 | 754 | 1,859 | 2,266 | 330 | 639 | 674 | 420 | 82 | 484 | 1,181 | 1,491 |
| Exercises of stock options | 133 | 156 | 115 | 156 | 128 | - | - | - | - | - | 160 | 199 | 94 | 61 | 38 |
| Cash dividends on common stock | 91 | 118 | 133 | 196 | 214 | 254 | 288 | 320 | 333 | 339 | 344 | 367 | 392 | 399 | 416 |
| Employee tax withholdings related to restricted share vesting | - | - | - | - | - | - | - | 9 | 8 | 6 | 10 | 24 | 38 | 71 | 64 |
| Other, net | -10 | -7 | -11 | -9 | -16 | -28 | -29 | -7 | -14 | -11 | -2 | 10 | -10 | -9 | -12 |
| NET CASH USED IN FINANCING ACTIVITIES | -275 | -788 | -1,117 | -741 | -501 | -630 | 565 | -1,313 | -243 | -1,087 | -604 | 1,953 | -1,753 | -2,222 | -2,331 |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | - | - | - | - | - | - | - | - | - | - | - | -4 | -58 | 73 | 9 |
| INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, INCLUDING CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE | - | - | - | - | - | - | - | - | - | - | - | -1,526 | 524 | -841 | 545 |
| LESS: INCREASE IN CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE | - | - | - | - | - | - | - | - | - | - | - | -2 | -1 | - | - |
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | - | - | - | - | - | - | - | - | - | - | 1,224 | -1,528 | 523 | -841 | 545 |